240.35 0.00 (0.00%)
After hours: 4:44PM EDT
|Bid||239.93 x 900|
|Ask||240.90 x 1100|
|Day's Range||239.30 - 241.89|
|52 Week Range||208.07 - 287.94|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||18.06|
|Earnings Date||Oct 14, 2019 - Oct 18, 2019|
|Forward Dividend & Yield||4.32 (1.80%)|
|1y Target Est||295.96|
UnitedHealth (NYSE:UNH) is the largest healthcare company in the world by revenue. That may sound pretty impressive, and with 130 million customers, it is. But, remember that most industrialized nations don't rely on employer-provided healthcare or supplemental Medicare insurance.Source: Ken Wolter / Shutterstock.com So, while the "world's largest" moniker is impressive, it really means it's the largest in the United States. And nowadays, it's hard to figure out if that's a curse or a blessing.There's no doubt that the 2020 election is all about whether the Democrats will actually run a candidate that will support a Medicare-for-all or single-payer system. But even if they do, it's likely that the U.S. will find a way to keep private insurers in business, simply because they employ so many people. And the transition to a new system would take a while.InvestorPlace - Stock Market News, Stock Advice & Trading TipsRegardless of the details, it's obvious that something has to be done about the current healthcare situation. The Republican Party has yet to present a plan on how to replace the Affordable Care Act and it doesn't seem like Congress is doing much of anything about anything. And the president can't simply sign an executive order changing the entire healthcare system. * 10 Undervalued Stocks With Breakout Potential All this has caused a certain consternation in the industry.You see, regardless of what happens, the companies in the healthcare sector simply need a clear understanding of where they stand so they can pursue the most efficient and effective ways to be profitable. As the old saying goes, the markets hate uncertainty. And that is exactly where this sector is right now. There are no ideas and there is no progress, so these stocks sit. The Bottom Line on UNH StockFor UNH, a good example is its Optum unit, which was a powerful profit center a couple years ago. This division managed outpatient clinics, had relationships with the major pharmacy benefit managers and was doing deals left and right.But now, there's less visibility on how best to grow, and the previous growth isn't enough to sustain UNH investors' imagination.As for UNH stock's dividend, given all the other sectors that are actually moving in a positive direction and delivering much better dividends -- real estate, financials, consumer goods -- UNH's wimpy but rock-solid 1.8% isn't much to get excited about. It's not like this dividend has been diminished because the stock has been on fire. For most companies, a rising stock price means a lower dividend yield.UNH stock is off 2% year-to-date and just over 8% in the past 12 months.My Portfolio Grader rates UNH stock a "C" at this point. That's a hold. There are much better sectors that have stronger growth potential. If you own the stock, it's not going to hurt you, but it's not going to help you much right now either.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post Is UnitedHealth Stock's Dividend Worth the Hassle for Investors? appeared first on InvestorPlace.
More than 80% of employers said they are planning to increase their health and wellness budgets this year, more than double compared to 2009 (34%), according to the 10th annual Optum Wellness in the Workplace study. The study also found that employers are increasingly embracing digital technology to engage workers in health and well-being programs. Since 2016, the proportion of employers using health-related mobile apps rose by 46%, with now close to three-quarters of respondents reporting that the apps helped increase employee participation.
Medicare for All faces a fight, but other health care reforms could wield a huge impact on providers, patients and health care stocks like UnitedHealth.
Even under normal circumstances, the healthcare stocks are prone to headline risk. Case in point, what happened to Sarepta (NASDAQ:SRPT) last night when the stock fell 15% on FDA news. Add to it that the U.S. is approaching another round of elections, and it makes healthcare stocks even riskier than normal -- through no fault of their own.In late June, I discussed three healthcare stocks to buy and for the most part the trades paid quickly. But since then, the stock markets in general had several mini corrections. We had fear flashes over geopolitical headlines, China's currency crisis and most recently, a bond-yield crash. So it's only fair to revisit those names again as the dust is settling. * 10 Undervalued Stocks With Breakout Potential So today we are discussing United Health (NYSE:UNH), Pfizer (NYSE:PFE), and Johnson & Johnson (NYSE:JNJ) stocks. I'll start with my conclusion first. All three are still good stocks to buy at these levels -- but for different reasons.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (JNJ)Johnson & Johnson is a long-time American success story. They are a global household name and their products are ubiquitous. From a valuation perspective, JNJ stock is relatively cheap because it has a modest price-to-earnings (P/E) ratio and pays a decent dividend.JNJ could be cheaper, but this is a management team that has proven itself through thousands of headline worries. The current headlines are nothing new for JNJ. So they have nothing but a temporary effect on the overall trajectory of JNJ stock.That said, Johnson & Johnson is still a buy here for anyone who's looking to add this sector to their portfolio. It is important to note that the company is probably past its talcum-powder headline risk by now even though it's not officially resolved. So I wouldn't take a full position all at once. Alternatively, I can sell puts below the current JNJ stock price to generate income from the intrinsic value of JNJ stock this way I don't even need a rally to win. United Health (UNH)United Health stock has performed the best of the three healthcare stocks since my last write up. It had an immediate 9% spike so from a trading perspective that was good timing.In addition, the overall thesis on UNH stock since then has not changed. It is still trailing the S&P 500 year-to-date. But over the last five years, UNH stock is up 180%, which is four times better than the S&P.After the July spike, UNH stock price faded the rally, but is has fallen into the same support zone from which it broke out. So this is the opportunity for the bulls to rinse-and-repeat another run.Technically speaking, UNH range is tightening into a point, so a move is coming in either direction. It is setting lower-highs and higher-lows at a point that coincides with the 12 month point-of- control for the stock. This is significant because this is literally where bulls and bears have agreed the most.So they will fight it out hard at this price once more and create support. As long as UNH stock holds above $240 per share, the bulls have a shot at retesting $260 or higher. There will be resistance along the way perhaps at $255 and most certainly at $256.50. * 10 Mid-Cap Dividend Stocks to Buy Now Conversely, there is the threat that the bears are able to break below $240 per share. If that happens, it could turn into a bearish head-and-shoulder pattern to target $224 per share. This is not a forecast but it's definitely a scenario that exists currently below UNH stock price. Pfizer (PFE)Pfizer stock was once bulletproof, but it can't even find footing of late. But maybe this time will be different. From current levels Pfizer stock can mount a revenge rally. Clearly so far, its stock performance metrics are poor so this has a lot of hopium tied to it.So this is definitely a tactical trade, and it should have a hard stop below $34 per share. This inadvertently is also a long-term five-year-old pivot point that also happens to be the point of control for that same period. So mathematically speaking, this is where bulls and bears love to disagree. This congestion should act as support.Simply put, if I buy PFE stock here, I literally have more upside potential than downside risk based on the 5-year price history. Fundamentally speaking, PFE is not expensive selling at 17 P/E and three times book. Yes, it can get cheaper, but this trade set up is tactical, so fundamentals don't matter as much for the short term.Longer-term, the Pfizer management team needs to re-earn Wall Street trust so that trades like this one would be with conviction. Maybe then the bulls will be able to drag the PFE stock out of the dumps and back in line with the overall stock market or at least its sector.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. Join his live chat room for free here. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post 3 Healthcare Stocks to Trade: UNH, JNJ and PFE appeared first on InvestorPlace.
The health care sector and the related exchange traded funds have been mired in political controversy this year and that is particularly true of health care services providers. What Happened As has been ...
UnitedHealthcare and the UAB Health System have finalized their agreement on a health insurance contract, ensuring that policyholders of UnitedHealthcare can continue to see UAB medical providers and utilize all UAB Health System entities. According to UAB, the new contract will be in effect for two years. “We are pleased that we were able to finalize an agreement with United Healthcare that will allow us to continue in our mission to provide the highest quality health care to their policy holders in Alabama,” UAB Health System CEO Will Ferniany said. “As the flagship hospital for the state, we provide medical services that no other health care facility can provide and we are committed to offering our services to everyone in the state of Alabama.” UnitedHealthcare also released a statement: “UnitedHealthcare and UAB Health System have finalized a new multi-year relationship that enables plan participants enrolled in UnitedHealthcare commercial and Medicare Advantage health plans to have continued access to all UAB facilities and physicians.
Dividend paying stocks like UnitedHealth Group Incorporated (NYSE:UNH) tend to be popular with investors, and for good...
UnitedHealth (UNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of UnitedHealth Group Incorporated and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Up until fairly recently, I used to be a big fan of Elon Musk and his vaunted company Tesla (NASDAQ:TSLA). However, a series of unnecessary controversies and unforced errors made me change my opinion. Granted, I still think the man is a genius. However, I wanted to avoid the coming train wreck in TSLA stock.Source: Sheila Fitzgerald / Shutterstock.com And man, was that ever the right decision. Year-to-date, Tesla stock is down more than 28%. Of course, this figure includes the effect of June and July's sympathy rally in TSLA. Without it, shares would have shed closer to 40%.For the bears, I say "never say never." In my opinion, TSLA stock is on the verge of falling into an overwhelmingly negative ecosystem. From internal troubles to external headwinds, Tesla is about to face an unprecedented series of challenges.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHere are three reasons to avoid Tesla stock (unless you want to short it): Recession Cuts Two Ways for TSLA StockOn Wednesday, the Dow Jones Industrial Average suffered an 800-point drop, the worst day of 2019 so far. Since no publicly traded company operates in a vacuum, virtually all stocks tanked. Even companies like UnitedHealth Group (NYSE:UNH) which has no exposure in China dipped severely. This drew fears of a coming recession.Logically, then, it wasn't a good day for Tesla stock, which does have exposure in China. In fact, before the U.S.-China trade war escalated in the past few weeks, TSLA was making an aggressive push toward dominating the electric vehicle market share in China. * 10 Stocks Under $5 to Buy for Fall You can say those plans got scuttled.But that's only the headline headwind. The other swing of the blade comes from a possible recession's associated risks. Primarily, I'm talking about oil prices. During the midweek session, the international oil benchmark Brent crude dropped more than 3% on weak global economic data.That's a massive problem for TSLA stock because it takes away the EV's principal selling point: eliminating pain at the pump.Thus, if we head into a recession, don't expect consumers to jump on EVs. By the way, Tesla's cars aren't that reliable, taking away another selling point and adding troubles to TSLA stock. Tesla Stock Could Get 'ICE-d'I believe most economists agree that we're headed toward at least a market correction, if not a recession. Given that we're on the longest bull market ever, I think that's a reasonable forecast.But let's say that we don't have a recession for whatever reason. Maybe President Donald Trump and Chinese President Xi Jinping engage in a "Titanic"-like bromance. Or maybe the Federal Reserve finally found the magic formula to quantitative easing.Would an extension of the bull market save Tesla stock? I highly doubt it because of the competition.As I argued last month, we're living in the golden age of the internal combustion engine, or "ICE" for short. While fossil-fueled cars are archaic compared to EVs, they offer astounding conveniences and performance at a great price.Previously, I used the example of a Toyota's (NYSE:TM) popular Camry: It's practical, sporty, reliable and affordable. Also, I think it's good looking. But the point is, modern ICE cars are combining so many attributes under one umbrella. On the other hand, because EVs represent relatively new technologies, they lack ICE cars' consumer friendliness.As an aside, consider General Motors' (NYSE:GM) 2020 Corvette. A mid-engine beast that resembles an Italian exotic, GM made the shocking announcement of selling their flagship for only $60,000. Who'd buy an EV under such an aggressive pricing environment?The innovation in ICE cars is bad news for TSLA stock. Same Old TeslaFinally, let's discuss the third reason to avoid TSLA stock: We're still dealing with the same old Tesla. Specifically, the company loves to overpromise and underdeliver.This has been a criticism that has dogged the company for years. Usually, this has revolved around car deliveries. But recently, the bearish assessment extends to product features, such as automated driving.In the past, Wall Street gave Tesla stock substantial leeway. After all, EVs represented an exciting new technology. And while traditional automakers forwarded ugly or otherwise uninspiring hybrids, Tesla cars were undeniably gorgeous. Stated differently, Tesla did EVs right.But the honeymoon phase is over. The Street wants to see hard numbers to back up the premium in TSLA stock. They also want Musk to stop making unnecessary errors and start taking his business seriously.Of course, some of the bullish arguments rest on the company doing exactly that. But for me, I'm going to read between the lines.As you likely know, Tesla has experienced a mass exodus of key executives. Most recently, chief technology officer JB Straubel stepped down from his post.You've got to wonder what's going on at Tesla. Executives at these types of organizations are overpaid and underworked. So it must take something extraordinary for them to give up such great money. Whatever the case, it's probably not conducive for TSLA stock.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks Under $5 to Buy for Fall * 5 Stocks to Avoid Amid the Ongoing Trade War * 7 5G Stocks to Buy Now for the Future The post 3 Reasons to Park Tesla Stock and Leave appeared first on InvestorPlace.
Myriad Genetics stock crashed Wednesday after the genetic-testing outlet unveiled new reimbursement challenges, dampening its 2020 outlook. Shares wiped out their gains after a breakout.
Teladoc's (TDOC) vast business presence in the growing telehealth industry with many deal wins and international expansion should drive long-term growth.
The Board of Directors of UnitedHealth Group , at its regularly scheduled meeting, authorized payment of a cash dividend of $1.08 per share, to be paid on September 24, 2019, to all shareholders of record of UnitedHealth Group common stock as of the close of business on September 16, 2019.
Rating Action: Moody's assigns Baa1 to Premier Health Partners' (OH) Ser. New York, August 13, 2019 -- Moody's Investors Service has assigned Baa1 underlying ratings to Premier Health Partners' (PHP, OH) proposed Hospital Facilities Revenue Refunding Bonds, Series 2019B (Premier Health Partners Obligated Group) and Series 2019C (Premier Health Partners Obligated Group). Moody's expects that these bonds will be issued in the variable rate mode and backed by letters of credit from PNC Bank, N.A.. Moody's maintains Baa1 ratings on existing revenue bonds of PHP.